Table 2. Dapsone Treatment Data.
| Treatment Data | Disease | ||
|---|---|---|---|
| Chronic Idiopathic Urticaria (n = 45) | Chronic Autoimmune Urticaria (n = 34) | Chronic Spontaneous Urticaria (n = 79) | |
| Time to initiating dapsone therapy, mo | |||
| Mean (SD) | 15.7 (36.8) | 8.2 (21.0) | 12.5 (31.2) |
| Median (range) | 5.0 (0.5-185.0) | 3.8 (0.5-124.0) | 4.0 (0.5-185.0) |
| Duration of dapsone therapy, mo | |||
| Mean (SD) | 10.0 (14.8) | 7.7 (12.0) | 9.0 (13.7) |
| Median (range) | 5.5 (0.5-72.0) | 3.5 (0.5-68.0) | 5.0 (0.5-72.0) |
| Maximum daily dapsone dose, mg | |||
| Mean (SD) | 117.8 (44.6) | 119.1 (43.3) | 118.4 (44.1) |
| Median (range) | 125.0 (25.0-200.0) | 125.0 (50.0-200.0) | 125.0 (25.0-200.0) |
| Improvement with dapsone, No./Total No. (%)a | 36/45 (80) | 26/34 (76) | 62/79 (78) |
| Time to improvement, mo | |||
| Mean (SD) | 1.2 (1.2) | 1.0 (0.6) | 1.1 (1.0) |
| Median (range) | 1.0 (0.5-7.0) | 1.0 (0.5-3.0) | 1.0 (0.5-7.0) |
| Complete response with dapsone, No./Total No. (%)b | |||
| All | 16/45 (36) | 13/34 (38) | 29/79 (37) |
| With improvement | 16/36 (44) | 13/26 (50) | 29/62 (47) |
| Time to complete response, moc | |||
| Mean (SD) | 5.0 (6.3) | 5.6 (3.1) | 5.2 (5.2) |
| Median (range) | 3.8 (1.0-29.0) | 5.0 (<0.5-12.0) | 4.0 (<0.5-294.0) |
| Sustained complete response, No./Total No. (%)d | |||
| All | 14/45 (31) | 13/34 (38) | 27/79 (34) |
| With complete response | 14/16 (87) | 13/13 (100) | 27/29 (93) |
| Duration of sustained complete response, mo | |||
| Mean (SD) | 7.2 (2.7) | 6.2 (5.0) | 6.7 (4.0) |
| Median (range) | 8.0 (2.8-11.0) | 4.0 (2.0-16.0) | 6.0 (2.0-16.0) |
| Able to taper therapy, No./Total No. (%) with sustained complete response | 11/14 (77) | 10/13 (77) | 21/27 (78) |
| Interval from sustained complete response to taper, mo | |||
| Mean (SD) | 3.0 (2.4) | 1.9 (1.8) | 2.4 (2.2) |
| Median (range) | 2.0 (0-6.5) | 1.3 (0-6.0) | 2.0 (0-6.5) |
| Experienced flare with therapy taper, No./Total No. (%) able to taper | 1/11 (9) | 2/10 (20) | 3/21 (14) |
| Able to discontinue, No./Total No. (%) with sustained complete response | 10/14 (71) | 8/13 (62) | 18/27 (67) |
| Achieved remission, No./Total No. (%)e | |||
| All | 4/45 (9) | 6/34 (18) | 10/79 (13) |
| With complete response | 4/16 (25) | 6/13 (46) | 10/29 (34) |
| Able to discontinue therapy | 4/10 (40) | 6/8 (75) | 10/18 (56) |
| Remission follow-up time after discontinuing dapsone, mo | |||
| Mean (SD) | 1.1 (1.1) | 3.4 (3.6) | 2.5 (3.1) |
| Median (range) | 0.8 (0-3.0) | 2.0 (0.3-10.0) | 2.0 (0.3-10.0) |
| Flare after discontinuing dapsone therapy, No./Total No. (%) | |||
| All | 6/45 (13) | 2/34 (6) | 8/79 (10) |
| With complete response | 6/16 (38) | 2/13 (15) | 8/29 (28) |
| Able to discontinue therapy | 6/10 (60) | 2/8 (25) | 8/18 (44) |
| Time to flare after discontinuing dapsone, mo | |||
| Mean (SD) | 3.3 (2.0) | 1.8 (1.3) | 2.9 (2.0) |
| Median (range) | 2.5 (0.8-6.0) | 1.8 (0.5-3.0) | 2.5 (0.5-6.0) |
a
Indicated by a decrease in pruritus, a decrease in duration and number of wheals, a decrease in number and frequency of chronic spontaneous urticaria episodes, or a decrease in systemic symptoms.
b
Defined as complete absence of urticaria, angioedema, and systemic symptoms.
c
Includes 28 of the 29 patients who achieved complete response; 1 patient achieved complete response in less than 0.5 months of dapsone therapy.
d
Defined as at least 2 consecutive months of complete response.
e
Defined as complete response with no subsequent flares to the end of medical record review.